BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

The Day In Review: SuperGen, Inc. (SUPG) Drug Disappoints


4/26/2006 6:10:46 PM

April 26, 2006 -- SuperGen said an interim analysis of a Phase II trial of its cancer drug showed that the compound was not beneficial; CV Therapeutics reported a sharply higher loss because of marketing costs for recently approved Ranexa; Vertex Pharma fell on a bigger loss; Celera will soon announce a genetic test for hepatitis C patients, showing which ones are likely to develop liver problems; NPS Pharma received European approval for its osteoporosis drug; Inspire Pharma will begin a Phase II trial of its antiplatelet drug; Spectrum and GPC Biotech said the data monitoring board recommended continuing the Phase III trial of its prostate cancer compound; BioMimetic set the terms for its upcoming IPO; LeMaitre Vascular made its initial IPO filing; and Bayer and Onyx said Nexavar has been given orphan drug status by the FDA for liver cancer. The Centient Biotech 200™ was down 44 points at 3714.18, a loss of 1.18%. More details...

Read at ChinaBio Today

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES